Joel Liederman, MaRS Innovation's vice-president of Business Development and Commercialization for physical sciences, is attending BioTransfer 2014 on March 18 to chair the Medical Devices Committee. This is the first year that…
Led by a $200,000 donation by Mr. Ralph Chiodo of Active Green + Ross, OtoSim Inc. provided 66 OtoSim™ simulation units to U of T.
Otoscopy, the diagnostic examination of the ear, is one of the most poorly acquired medical skills in students because traditional methods of study rely on lectures and print material. Using the OtoSim™ simulation unit allows students to interactively improve otoscopy skills before they reach the clinic.
Dr. Andrew (Andy) Sinclair, OtoSim’s CEO, was interviewed by PharmaBoadroom.com on October 10, 2013 to discuss the company’s success and plans for the future. OtoSim's otoscopy training device is revolutionizing…
Through the collaboration, MaRS Innovation and technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will jointly identify and fund high-potential opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, which include the University of Toronto and its affiliated teaching hospitals.
Dr. Raphael Hofstein, president and CEO of MaRS Innovation.
“We are looking forward to working with Johnson & Johnson Innovation,” said Dr. Raphael Hofstein, president and CEO, MaRS Innovation. “There are many high quality opportunities coming out of the Toronto research community, and these opportunities can benefit from our close collaboration.”
Through the agreement, Johnson & Johnson Innovation will provide funding over a three-year period to support promising individual projects based on joint due diligence, which will be leveraged with financial support from MaRS Innovation.
This program provides a simple mechanism to connect researchers with MI’s industry partners. The process and application form are intentionally brief to save researchers time and allow MI’s partners to review a wide range of remarkable technologies within the Toronto academic community in a short period of time.
Parimal Nathwani, vice-president, Life Sciences, MaRS Innovation.
“Many granting programs require an industry partner, but leave finding that partner to the researcher,” says Parimal Nathwani, vice-president of life sciences at MI. “Our Industrial Partnership Program completes that step for them. We also know researchers within our member institutions are incredibly busy, which is why we’ve adopted a streamlined process to save them time.”
The program is open to any researcher affiliated with our 16 member institutions working on technologies in:
Bedside Clinical Systems to bring paediatric care solution to U.S. hospitals TORONTO, Canada (October 24, 2013) — Bedside Clinical Systems (BCS)’s flagship solution, Bedside Paediatric Early Warning System (BedsidePEWSTM), has…
This op-ed on Canadian biotechnology and the knowledge economy appeared in The Hill-Times (subscription required), Canada’s politics and government newsweekly, September 9:
Obesity, cancer, heart disease and stroke, diabetes, Parkinson’s disease, Alzheimer’s, or the more general stresses of an aging population: no matter which area of concern holds our collective gaze from moment to moment, improving health outcomes and healthcare is the No. 1 challenge for the world’s economy.
Canada has the holistic approach and translational research necessary to address health care’s pervasive challenges, with particular strengths in biotechnology.
In 2007, the Government of Canada made advancing translational research a top priority through the Science and Technology Strategy, with emphasis on cancer, metabolic disorders and, most recently, neurology, as part of the government’s response to the burdensome realities of neurodegenerative disorders.
Scientific research has made significant progress in unraveling the underlying causes of disorders such as Parkinson’s disease and Alzheimer’s disease, but translating these findings into useful clinical treatments is the key to attaining meaningful accomplishments. Only clinical treatment successes will alleviate pressure on the economy.
Transformational research is the essential first step in this process, but even more importantly, it needs to be put in the hands of those who can translate it into realistic and useful outcomes for patients in particular and society in general.
Thanks to research analytics that capture publications, citations, and other significant metrics, we know Canadian researchers punch above their weight, particularly in medical research. Canada’s challenge is not the quality or quantity of our research ideas but our ability to commercialize those ideas and translate them into market-ready products.
Designed to bridge the challenging gap between innovation and commercialization, the CECR program matches clusters of research expertise with the business community to share the knowledge and resources that bring innovations to market faster.
MaRS Innovation was among the first CECRs to be created in 2008, largely based on the founding belief of its members that Toronto is a fertile research land for precisely this kind of translational activity.
University of Toronto PhD student Lian Len with a prototype tissue printer. Photo courtesy of Dominic Ali (University of Toronto)
“It’s one thing to invent a machine that prints skin, but it’s a whole other challenge to bring what seems like the domain of mad science to mass production,” Matthew Braga wrote in “Looking for ways to get ‘skin’ in the game,” published in the Financial Post on July 15.
The article focuses on MaRS Innovation’s (MI) and the Innovations and Partnerships Office’s (University of Toronto) joint efforts to commercialize the bio printer, a “prototype 3D printer that, instead of extruding layers of plastic and other inorganic materials into physical shapes, builds layer upon layer of cell-laden tissue, a process that could lead to the cheap, rapid production of human skin.”
Braga’s article was syndicated in the Regina Leader Post, the Saskatoon Star-Phoenix, and the Vancouver Sun, among other Canadian publications.
MI’s Fanny Sie and Shotlst Co-founder Matt Ratto talk bioprinting, healthcare, civil rights and home manufacturing with Steve Paikin
Fanny Sie, project manager in physical sciences and medical devices with specialization in medical imaging, appeared on TVO’s The Agenda on June 5, 2013 to discuss 3D printing.
MaRS Innovation Project Manager Fanny Sie discusses 3D printing, the Bioprinter technology and the implications for society and human health on TVO’s The Agenda.
Sie manages the Bioprinter technology, which was touched upon during the interview. The bioprinter was invented by Axel Guenther, a professor in the University of Toronto’s Department of Mechanical and Industrial Engineering, PhD student Lian Leng and a team of other researchers.
The Globe and Mail covered the Bioprinter’s development on January 20, 2013; an excerpt of their interviews with Leng and Guenther was included in the program.
Bioprinting and the Internet of Things
The Agenda’s 3D printing episode also included a second segment exploring its implications for home manufacturing and civil liberties. The guests included Matt Ratto, assistant professor in U of T’s Faculty of Information and co-inventor and CEO of Shotlst (a UTEST company).
Professor Matt Ratto, co-founder of Shotlst and director of the Critical Making Lab, discusses 3D printing, home manufacturing and civil liberties on TVO’s The Agenda.
Ratto described his experience downloading and printing the Liberator, a gun that can be printed using 3D printing technology, to better understand the process required and the resulting gun’s capabilities.
Raphael Hofstein, president and CEO of MaRS Innovation
Dr. Raphael Hofstein, president and CEO of MaRS Innovation, delivered a guest lecture on February 1,2013 at the Revitalizing Medical BioTechnology Commercialization symposium, hosted by Stanford University‘s NIH Graduate Training Program in Biotechnology.
The one-day event brought academic, venture capital and industry thought leaders together to reflect on the challenges facing technology transfer processes across the biotech industry.
TORONTO, Nov. 25, 2013 – MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, today announced a new collaboration with Johnson & Johnson Innovation and its affiliate Janssen, Inc., in Canada to advance early-stage technologies related to human health in therapeutics, medical devices, and diagnostics.
